GreenLight Biosciences Holdings, PBC: management transactions · United States · SEC (Form 4)

About GreenLight Biosciences Holdings, PBC

GreenLight Biosciences Holdings, PBC (ticker: GRNA) is a U.S.-listed agricultural biotechnology company traded on the NASDAQ market in the United States. Headquartered in Lexington, Massachusetts, United States, the company was founded in 2008 and has built its strategy around a proprietary cell-free RNA production platform. GreenLight’s core thesis is that RNA can be manufactured at scale and deployed as a precise biological tool for agriculture and related life-science applications, offering a differentiated alternative to conventional chemical inputs. The company’s business is centered on the research, development, manufacturing, and commercialization of RNA-based products for plant protection and pollinator health. GreenLight uses RNA interference (RNAi) to target specific pests or pathogens with high selectivity. Its first commercial products are Calantha™, an EPA-registered bioinsecticide for Colorado potato beetle control in potatoes, and Norroa™, an RNA-based treatment for varroa mites in honeybees. The company is also advancing a broader pipeline across insecticides, fungicides, and herbicides, including programs aimed at fungal diseases in grapes and strawberries and at herbicide-resistant weeds. From a competitive standpoint, GreenLight positions itself as an early leader in applied RNA for agriculture. Its differentiation lies in combining biological precision, environmental compatibility, and industrial-scale RNA manufacturing know-how. The company emphasizes its patent portfolio, scale-up capabilities, and years of technical development as key strategic assets. That said, the investment profile remains that of an emerging commercialization-stage biotech: execution risk, regulatory dependence, and adoption risk remain central considerations, even as the company begins to convert its platform into marketable products. GreenLight’s operating footprint is mainly in the United States, with facilities around Boston, Massachusetts, plus manufacturing and R&D sites in Rochester, New York, Durham, North Carolina, and additional research operations in Spain. Recent notable developments include the EPA registration and launch of Norroa in 2025, the commercial rollout of Calantha, and the October 2025 filing of regulatory dossiers in the United States, the European Union, and Brazil for an RNA-based fungicide targeting grape powdery mildew. For investors, GRNA is best viewed as a thematic growth name in agricultural innovation: potentially high upside if the RNA platform scales, but still carrying substantial clinical-style commercialization and regulatory risk.